Pay Attention to Diagnosis and Treatment of Gastrointestinal Stromal Tumors
10.3969/j.issn.1008-7125.2019.05.001
- Author:
Ming WANG
1
Author Information
1. Department of Gastrointestinal Surgery, School of Medicine, Shanghai Jiao Tong University
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Gastrointestinal Stromal Tumors;
Imatinib Mesylate;
Molecular Targeted Therapy;
Precision Medicine;
Receptor Tyrosine Kinase Inhibitors
- From:
Chinese Journal of Gastroenterology
2019;24(5):257-263
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the gastrointestinal tract. The receptor tyrosine kinase inhibitor imatinib mesylate is used for the standard treatment of GIST and has achieved remarkable results. Thus, GIST has become the most successful model for targeted therapy of solid tumors. GIST is quite different from other gastrointestinal tumors in pathological diagnosis, endoscopic and imaging diagnosis, surgical principles and drug treatment. Multidisciplinary collaborative model plays an important role in the diagnosis and treatment of GIST. Contemporary medicine has entered a new era of standardized, individualized and precise diagnosis and treatment at molecular level. Clinicians, especially those engaged in gastrointestinal tumors, should pay attention to and standardize the diagnosis and treatment of GIST, and apply the experience gained from GIST to the clinical practice of precision medicine.
